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Abstract: Biotechnology is typically associated with the centres of learning and firms in industrialised 
countries but usually not with institutions in developing countries. Developing nations are however, 
becoming active in this field and are increasingly using recombinant methods to produce new and innovative 
health products for their populations. Here we will examine health biotechnology development in two 
developing countries, Brazil and Cuba. We will compare the major characteristics of their health 
biotechnology sectors and highlight factors that have shaped their development in order to understand better 
what main factors and conditions can promote health biotechnology innovation in developing countries. 
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Introduction 
Even though the biotechnology sector is 
dominated by some of the richest countries in the 
world, developing countries are increasingly 
making their mark on the field. Biotechnology can 
be used to address various health problems of 
people in developing countries and contribute 
towards better global health [1-3]. Furthermore, 
developing countries themselves have been shown 
to be active in this field; they are engaged in health 
biotechnology research and are increasingly using 
recombinant methods to develop new and 
innovative products for their populations [4]. 
There is increasing recognition that instead of 
importing solutions for their health problems, 
developing countries can innovate and find 
solutions locally [5]. Our previous research on 
health biotechnology innovation has supported 
this observation [6]. We examined health 
biotechnology development in seven developing 
countries that have demonstrated successes in this 
field. Amongst them were Brazil and Cuba [7,8]. 
Here we will compare the development in these 
two countries and discuss the major factors that 
have shaped the characteristics of their health 
biotechnology sectors. We chose Brazil and Cuba 
as they are amongst the most advanced countries 
in the Latin American and the Caribbean region in 
terms of health biotechnology. They share 
important characteristics that can influence 
activities in this field but have at the same time 
followed quite different routes in their 
developments. 
What Brazil and Cuba share  
Both Brazil and Cuba are developing countries 
that fit the World Bank’s lower middle income 
category [9]. The GDP/Capita is US$7770 for 
Brazil (ranked 63 of 177 countries) and US$5259 
for Cuba (ranked 91 of 177 countries) and their 
ranks in the human development index are 52nd 
for Cuba and 72nd for Brazil [10]. On the other 
hand Cuba and Brazil share the characteristic that 
they have a relatively high educational level. Figure 
1 demonstrates that both Cuba and Brazil have 
populations with relatively high education levels 
with education indices well beyond the averages  
 
for developing countries. Life expectancies are also 
relatively high in both countries, especially in Cuba 
where it has reached developed countries’ levels.  
In addition, Brazil and Cuba share the 
characteristic that their governments emphasised 
health biotechnology development relatively early 
on as biotechnology was taking off in the 1970s 
and 1980s. In Brazil two programmes that featured 
biotechnology development were launched in the 
1970s by Brazil’s National Research Council 
(CNPq), the Integrated Programme on Genetics 
(PID) and the Integrated Programme on Tropical 
Diseases (PIDE). In 1981, the government set up 
the National Biotechnology Programme 
(PRONAB) to integrate activities in the different 
types of biotechnology. Since then further 
programmes have been set up to promote 
biotechnology development and despite frequent 
turnover, the governments have continued to 
support biotechnology [7,11]. 
The Cuban government also singled out 
biotechnology as a promising field in the early 
1980s and gave strategic importance to its 
development [8,12]. They promoted education in 
the field and set up various institutions to engage 
in biotechnology. They also created an 
interdisciplinary forum for biotechnology 
development the so called Biological Front, in 
1981 which had the task to explore the potentials 
of biological sciences for Cuba. The support of the 
Cuban government for biotechnology 
development did not waiver during the hardship of 
the so called ´Special Period´, in the early 1990s 
after the disintegration of the Soviet Union and 
Cuba’s major Eastern European markets. 
An additional characteristic that Cuba and 
Brazil share that can influence health 
biotechnology development is that they are 
members of the World Trade Organisation 
(WTO). Both countries have been members of the 
WTO since 1995 and are signatories of the Trade-
Related Aspects of Intellectual Property (TRIPS) 
agreement. They started to implement TRIPS in 
2005, which will make it difficult for them to 
export products without licensing if those are 
already patented by others. Both countries have 
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Figure 1: Education and Life Expectancies in Brazil and Cuba Compared to Other                 
Developing Countries (Source: UNDP, Human Development Report 2004) 
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been driven to revise their intellectual property 
systems and set up more stringent patent 
regulations than they previously had. Their health 
biotechnology sectors therefore are gearing up to 
become innovative in order to sustain and surpass 
their current activity levels. 
How Brazil and Cuba differ 
With regards to the health biotechnology sector 
the major difference between Brazil and Cuba are 
the types of activities they emphasise. In Brazil the 
focus has been stronger on more fundamental 
research and publishing in high impact journals 
whereas in Cuba the emphasis has been more on 
developing new and innovative health 
biotechnology products. This does not mean that 
Cuba does not have its share of scientific 
publications or that Brazil has not developed an 
innovative health biotechnology product but 
rather the bulk of activities seem to be focused on 
these different types of activities, respectively. In 
Figure 2 we show the number of papers published 
in health biotechnology in the international peer 
reviewed literature by authors in the two countries 
over the period from 1991 to 2002. As can be seen 
the level of publishing is substantially higher in 
Brazil than in Cuba. This can partly be explained 
by a much larger population size and much larger 
scientific community in Brazil than in Cuba. The 
citation rate of Brazilian papers is also higher than 
Cuban papers, or 0.63 average relative citation 
level (1991-2002) for Brazil versus 0.45 for Cuba 
[13]. Brazil also has significant strengths in 
agricultural biotechnology. For example, it was the 
first country to sequence the genome of a plant 
pathogen, Xyllella fastidosa, which is a bacterium 
that attacks citrus fruits [21]. 
 
When comparing the product portfolios in 
health biotechnology of Cuba and Brazil, the latter 
displays a more modest success. A recombinant 
human insulin product developed in the 1990s by 
the Federal University of Minas Gerais and the 
Brazilian biopharmaceutical firm Biobrás was 
identified by Brazilian experts to be one of the 
best examples of Brazilian innovation in this field 
[7]. Brazil also has a strong diagnostic sector and 
has for example developed a recombinant antigen 
test for Chagas disease [14]. In general Brazil has 
had difficulties capitalising on its strong 
publication record in biotechnology, as the 
Minister of Science and Technology, Eduardo 
Campos stated ‘Brazilians get lost between basic 
research and its transformation into technology, 
between academic life and the manufacturing 
system [15]. 
Cuban health biotechnology has, however, a 
very applied focus with an impressive product 
portfolio. One of the early examples of Cuban 
innovation in this field is the world’s first 
meningitis B vaccine developed in the late 1980s. 
Cuban innovation has continued and includes, for 
example, humanized anti epidermal growth factor 
receptors monoclonal antibodies against head and 
neck tumours as well as the world’s first human 
vaccine with a synthetic antigen against pneumonia 
and meningitis introduced in 2004 [16,17]. James 
Larrick, a biotechnology expert and entrepreneur 
in Palo Alto, California says for example, the 
following about Cuban biotechnology: “Their 
pipeline is very, very deep now …. It’s gone into 
an adolescence and it’s looking pretty good” [18].  
Cubans have been active in licensing and setting 
up strategic alliances and joint ventures based on 
Cuban biotechnology with companies around the 
world. They have, for example, made an 
agreement with GlaxoSmithKline to produce and 
distribute the meningitis B vaccine in Europe and 
North America; a joint venture with the Canadian 
firm YMBiosciences to develop and market cancer 
therapeutics; an agreement with the US firm 
CancerVax to undertake joint development and 
licensing of Cuban cancer vaccines; a strategic 
alliance with the Indian firm Panacea Biotec to 
manufacture hepatitis B vaccine in India; and joint 
ventures with the Chinese firms Beijing 
Jingyitaixiang Technology Development, Shanxi 
Xinyutong Material Commerce and China 
International Science Centre for cancer research. 
Despite a relatively small population size and 
limited economic resources Cuba has been able to 
build up an enviable track record in biotechnology 
products. 
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What explains the differences in health 
biotechnology between Brazil and Cuba  
Innovation is a complex process so a multitude 
of factors and conditions can explain the 
differences in health biotechnology development 
between Brazil and Cuba. Here we will briefly 
highlight a few factors we believe to have played a 
strong role in shaping the development but a more 
complete discussion of those factors is beyond the 
scope of this paper.  
 
1. Governmental involvement. 
In Brazil promoting health biotechnology has 
been the mandate of the Ministry of Science and 
Technology whereas in Cuba the development of 
the sector has been under the auspice of the 
Council of State, the highest decision making 
power in the country and championed by its 
President Fidel Castro. As a result the successes 
in Brazil have been confined to the science and  
 
 
 
 
 
 
 
 
 
 
technology sector and not well aligned with 
industrial and commercialisation development.  
 
In Cuba the biotechnology sector has had a 
high national priority and its development has 
been tightly connected to industrial and foreign 
affairs policies. An emphasis on health 
biotechnology fits especially well with the Cuban 
strategy of promoting health, education and 
sciences. 
 
2. Domestic linkages. 
In Cuba the public research institutes, such as 
the Centre of Genetic Engineering and 
Biotechnology (CIGB, Havana), the Finlay 
Institute (Havana) and the Center of Molecular 
Immunology (CIM, Havana) are the main actors 
in health biotechnology. They, for example, 
published over 97% of health biotechnology 
papers covered in the international peer reviewed 
journals from 1991 to 2002 [13]. The institutes 
cover a breath of activities including research, 
development, manufacturing, quality control and 
commercialisation. The fact that all these 
activities are under the same leadership is likely 
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Figure 2: Number of papers in health biotechnology in Brazil and Cuba, 1991-2002  
Source: Science-Metrix (data from Science Citation Index Expanded, ©Thomson ISI) 
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to make the knowledge flow and integration 
between these activities easier. 
In Brazil, universities, together with such 
public research institutions as the Oswaldo Cruz 
Foundation (FIOCRUZ, Rio de Janeiro) and the 
Institute Butantan (Sao Paulo), are the main 
actors in the health biotechnology sector. 
Universities published 80% of the Brazilian 
health biotechnology papers in the international 
peer reviewed journals in 1991-2002, whereas the 
public research institutes published 31% [13]. 
Both of the main public research institutes in 
Brazil share with the Cuban institutes the 
characteristic of being involved in a variety of 
activities in health biotechnology which include, 
for example, manufacturing. Knowledge flow to 
and from Brazilian universities and public 
research institutes is, however, limited as they are 
not well connected to enterprises [7,19]. 
University professors are often sceptical about 
close associations with companies and until 
recently there was a decree prohibiting university 
professors to be employed by industry. A recent 
Innovation Law altered this and makes it 
possible for university professors to work for a 
limited time for the private sector. As a result 
knowledge may flow more easily between 
universities and the private sector in Brazil and 
the formation of university spin-off companies 
can be stimulated. 
 
3. Connection with the health system. 
The connections between the main actors of the 
health biotechnology sector and the health system 
are much better aligned in Cuba than in Brazil. In 
Brazil, public procurement policies demand that 
the lowest cost products are purchased by the 
public health system. This requirement may 
constitute a responsible public policy but can 
squeeze out local biotechnology endeavours 
especially when large multinational companies 
temporarily underbid local suppliers. The public 
procurement policy led the health system in Brazil 
to choose recombinant insulin from Novo 
Nordisk (Bagsværd, Denmark) over a locally 
developed product produced by the Brazilian 
biotechnology company Biobrás. The price 
difference between these products was small but 
the decision to purchase led to the downfall of the 
Brazilian biotechnology company and ultimately it 
was acquired by Novo Nordisk [7,20].  
Cuba’s health biotechnology sector is closely 
aligned with the health system. Cuban products are 
preferred to be imported ones in order to save 
foreign currency. The government has also 
harnessed the expertise in the health 
biotechnology sector to address domestic health 
problems. That was, for example, the case when 
the meningitis B vaccine was developed. A special 
research group was formed to come up with a 
vaccine candidate to address a meningitis outbreak 
in the country. In general the knowledge flow 
between the health system and the health 
biotechnology sector is active and the information 
from health practitioners has been said to spur 
innovative ideas [8]. 
It is evident that Cuba and Brazil have different 
strengths and weaknesses in the health 
biotechnology field. There is tremendous scope 
for them to learn from each other’s experience. So 
far there has been limited collaboration between 
these two countries in the health biotechnology 
field. The presidents of Brazil and Cuba have 
however singled biotechnology out as a field where 
they intend to promote closer co-operation [22]. 
From our analysis it will certainly be a mutual 
advantage for these two countries to collaborate. 
To combine the scientific strengths of Brazil with 
the product development expertise of Cuba will be 
for the benefit of both countries.   
Conclusion 
In general, the bulk of health innovation in the 
world is focused on the lucrative markets of the 
industrialized countries. Limited efforts are aimed 
at developing countries’ health needs. With 
rampant health problems in developing nations 
and massive health inequities in the world, it 
should ultimately be the goal of health 
biotechnology sectors in developing countries to 
develop new and innovative health products for 
their own populations rather than to focus solely 
on the markets in richer countries. It is 
encouraging when we observe successes in this 
respect and see developing countries that have 
built up impressive capacity to address health 
needs in this field as is the case of Brazil and Cuba. 
Still, health biotechnology is a risky field and it is 
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difficult to predict how these countries will fare in 
the future. They will face stiff competition from 
industrialized countries that have actively 
promoted the biotechnology field for many years. 
They will also face competition from other 
developing countries active in this field such as 
India. It remains to be seen what approach is 
going to be successful in the long run to follow 
product led or science led development. In any 
event these two countries have much to learn from 
each other and to teach other countries in the 
region and around the world.  Stronger south to 
south collaboration between countries such as 
Brazil and Cuba is a promising strategy that can 
strengthen the rhythm of biotechnology created 
for and by developing countries.  
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